These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32575619)

  • 1. Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma.
    Ruiz-Rodado V; Seki T; Dowdy T; Lita A; Zhang M; Han S; Yang C; Cherukuri MK; Gilbert MR; Larion M
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32575619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
    Chaumeil MM; Radoul M; Najac C; Eriksson P; Viswanath P; Blough MD; Chesnelong C; Luchman HA; Cairncross JG; Ronen SM
    Neuroimage Clin; 2016; 12():180-9. PubMed ID: 27437179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment.
    Subramani E; Radoul M; Najac C; Batsios G; Molloy AR; Hong D; Gillespie AM; Santos RD; Viswanath P; Costello JF; Pieper RO; Ronen SM
    Cancer Res; 2020 Nov; 80(22):5098-5108. PubMed ID: 32958546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
    Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
    Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase.
    Izquierdo-Garcia JL; Cai LM; Chaumeil MM; Eriksson P; Robinson AE; Pieper RO; Phillips JJ; Ronen SM
    PLoS One; 2014; 9(9):e108289. PubMed ID: 25243911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.
    Chaumeil MM; Larson PE; Woods SM; Cai L; Eriksson P; Robinson AE; Lupo JM; Vigneron DB; Nelson SJ; Pieper RO; Phillips JJ; Ronen SM
    Cancer Res; 2014 Aug; 74(16):4247-57. PubMed ID: 24876103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma.
    Khurshed M; Molenaar RJ; Lenting K; Leenders WP; van Noorden CJF
    Oncotarget; 2017 Jul; 8(30):49165-49177. PubMed ID: 28467784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic reprogramming in mutant IDH1 glioma cells.
    Izquierdo-Garcia JL; Viswanath P; Eriksson P; Chaumeil MM; Pieper RO; Phillips JJ; Ronen SM
    PLoS One; 2015; 10(2):e0118781. PubMed ID: 25706986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
    Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
    Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance spectroscopy for the study of cns malignancies.
    Ruiz-Rodado V; Brender JR; Cherukuri MK; Gilbert MR; Larion M
    Prog Nucl Magn Reson Spectrosc; 2021 Feb; 122():23-41. PubMed ID: 33632416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GABA, glutamine, glutamate oxidation and succinic semialdehyde dehydrogenase expression in human gliomas.
    Hujber Z; Horváth G; Petővári G; Krencz I; Dankó T; Mészáros K; Rajnai H; Szoboszlai N; Leenders WPJ; Jeney A; Tretter L; Sebestyén A
    J Exp Clin Cancer Res; 2018 Nov; 37(1):271. PubMed ID: 30404651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated Metabolomics and Lipidomics Analyses Reveal Metabolic Reprogramming in Human Glioma with IDH1 Mutation.
    Zhou L; Wang Z; Hu C; Zhang C; Kovatcheva-Datchary P; Yu D; Liu S; Ren F; Wang X; Li Y; Hou X; Piao H; Lu X; Zhang Y; Xu G
    J Proteome Res; 2019 Mar; 18(3):960-969. PubMed ID: 30596429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive in vivo assessment of IDH1 mutational status in glioma.
    Chaumeil MM; Larson PE; Yoshihara HA; Danforth OM; Vigneron DB; Nelson SJ; Pieper RO; Phillips JJ; Ronen SM
    Nat Commun; 2013; 4():2429. PubMed ID: 24019001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities.
    Garrett M; Sperry J; Braas D; Yan W; Le TM; Mottahedeh J; Ludwig K; Eskin A; Qin Y; Levy R; Breunig JJ; Pajonk F; Graeber TG; Radu CG; Christofk H; Prins RM; Lai A; Liau LM; Coppola G; Kornblum HI
    Cancer Metab; 2018; 6():4. PubMed ID: 29692895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters.
    Viswanath P; Najac C; Izquierdo-Garcia JL; Pankov A; Hong C; Eriksson P; Costello JF; Pieper RO; Ronen SM
    Oncotarget; 2016 Jun; 7(23):34942-55. PubMed ID: 27144334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2.
    Borodovsky A; Seltzer MJ; Riggins GJ
    Curr Opin Oncol; 2012 Jan; 24(1):83-9. PubMed ID: 22080945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration.
    Cao H; Zhu G; Sun L; Chen G; Ma X; Luo X; Zhu J
    Eur J Med Chem; 2019 Dec; 183():111694. PubMed ID: 31561044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
    Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
    J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
    Lazovic J; Soto H; Piccioni D; Lou JR; Li S; Mirsadraei L; Yong W; Prins R; Liau LM; Ellingson BM; Cloughesy TF; Lai A; Pope WB
    Neuro Oncol; 2012 Dec; 14(12):1465-72. PubMed ID: 23090985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate.
    Dexter JP; Ward PS; Dasgupta T; Hosios AM; Gunawardena J; Vander Heiden MG
    J Biol Chem; 2018 Dec; 293(52):20051-20061. PubMed ID: 30381394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.